Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...